Introduction
Probiotics are defined by the World Health Organization as "live microorganisms, which when consumed in adequate amounts confer health and benefit to the host" [1] . Although most commonly consumed worldwide in the form of yogurt or other fermented dairy products, probiotics are found and administered in many different forms, including a wide variety of dietary supplements and functional foods. Consumption of probiotics in their various forms is common and increasing rapidly. Within the United States, 3.9 million adults used probiotic or prebiotic supplements in 2015da fourfold increase from 2007 [2] . Sales figures suggest that probiotics are one of the supplement categories most often purchased by consumers. Whereas overall growth in the nutritional supplement industry slowed to 5% in 2014, probiotics grew 14.2% with nearly $1.4 billion in sales [3] . In addition to widespread use among consumers, a recent study revealed that 96% of hospitals used probiotics as part of inpatient clinical care [4] . The increasing use of probiotics in both hospitals and among the public at large demonstrates the increasing public health importance of clinical research on probiotics.
Probiotics, altered gut microbiota, and disease
A rapidly growing evidence base suggesting a variety of health benefits supports the increasingly common use of probiotics. More than 25 diseases or health conditions have been associated with the microbiota in the gastrointestinal tract, ranging far beyond gastrointestinal (GI) health into the realms of autoimmune disease, emotional health, and other areas [5] . Although the relationship between the microbiota and human health is broad ranging and the literature continues to expand, the health conditions that have been most consistently associated with the composition and activity of the microbiota are GI in nature. Probiotics are believed to provide an important role in human health by providing a protective effect on the microbiota in the GI tract through both colonization and transient activity, depending on the species. Probiotics have shown therapeutic benefits in adults and children across a broad range of health conditions, including autoimmune diseases [6] [7] [8] [9] , emotional disorders [10, 11] , and even as part of a potential treatment This study was supported in part by National Institutes of Health (NIH) grant no. R24 AT001293 from the National Center for Complementary and Integrative Health (NCCIH) and the University of Maryland School of Medicine Summer Program in Obesity, Diabetes, and Nutrition Research Training (NIH grant T35 DK095737). All authors were responsible for the manuscript preparation, revision, and publication decisions, and have read and approved the final manuscript. The authors have no conflicts of interests to declare.strategy for obesity [12] [13] [14] . However, the effects of probiotics have been most studied in GI conditions such as acute infectious diarrhea, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). Antibiotic therapy typically is prescribed for infectious diarrhea, which has been shown to reduce the diversity of intestinal microbiota. The two main IBD conditions, Crohn's disease and ulcerative colitis, also are associated with a reduced microbial diversity [5] . Although the exact mechanisms of action are unknown, the use of probiotics is thought to increase microbial diversity by improving the balance of organisms within the intestinal tract and reducing the risk for colonization by pathogenic bacteria [15, 16] . The clinical evidence surrounding probiotics for GI conditions is the focus of this overview.
Although probiotics have been shown to be efficacious in many randomized controlled trials (RCTs) and systematic reviews for a variety of health conditions, more precise evidence is needed to translate the growing evidence base to appropriate clinical practice. For instance, probiotics often are recommended in clinical practice without the necessary specification of numerous important factors related to the probiotic and the health condition for which they are being recommended. Probiotics are most broadly categorized by their genus (e.g., Lactobacillus), followed by their species (e.g., acidophilus), and most specifically, their strain (e.g., NCFM). The clinical effects of probiotics depend on many factors, including the species and strain of the probiotic. Different strains of the same species can yield heterogeneous clinical results [17] . One striking example is the vastly different effects noted among different strains of Escherichia coli species. E. coli 0157:H7 is a food-borne pathogen that can cause hemorrhagic diarrhea, kidney failure, and death. Within the same species, E. coli Nissle 1917 is a probiotic supplement that has been shown to improve IBD, IBS, and other GI disorders [18] [19] [20] . Despite the heterogeneity of effect of different strains of the same species, strains are rarely specified on most probiotic foods and supplements. This type of heterogeneity in effect often results in discrepancies between clinical outcomes of probiotic interventions. Combinations of different probiotic species and strains within the same capsule also introduce additional uncertainty due to unknown and poorly studied interactions between probiotic species. Additionally, the effective dosage of probiotics varies by species and strain. Probiotic dosage is most often measured as colony-forming units (CFU), and recommendations and clinical effects vary depending on the species and strain used and the pathogen or disease targeted [21] . Thus, identifying species and strains and specifying dosages is critically important to understanding how probiotics may or may not be effective for specific conditions. Lastly, even if the species, strains, and dosages are specified and concordant with the scientific literature, there are currently no product purity or labeling standards for probiotics to ensure that what is listed on the probiotic supplement label is actually in the bottle. The best current process to ensure probiotic purity and bottle-to-bottle consistency is third-party laboratory certification, which is flawed due to heterogeneity in testing methods between the various laboratories.
In addition to these confounding factors related to the probiotic intervention, factors related to the design of the clinical trial evaluating the probiotic also influences clinical outcomes. The specific outcomes studied and how they were assessed, the duration of probiotic treatment, and the length of follow-up should be clearly defined to more precisely describe the effects of probiotic treatment. The clinical heterogeneity observed in many studies and in clinical practice is a function of the many factors that can influence probiotic efficacy. Thus, the purpose of this review was to summarize the current evidence of probiotic therapy for GI symptoms to help provide more precise guidance for clinical use and to identify future needs for probiotics research. Systematic reviews and meta-analyses of probiotic interventions for GI-related medical conditions performed for the Cochrane organization will be the focus of this overview.
Cochrane and systematic reviews of probiotics Cochrane, which was founded in 1983 as the Cochrane Collaboration, is one of the first and most highly regarded organizations focused on the production and dissemination of systematic reviews of health care interventions. It is an international nonprofit organization that currently includes >37 000 contributors, mostly volunteers, from more than 130 countries [22] . Cochrane reviews aim to be unbiased; Cochrane does not accept commercial funding and has policies to guard against both commercial and noncommercial conflicts of interest in the production of reviews. Cochrane reviews are methodologically rigorous and follow structured and transparent methods outlined in the Cochrane Handbook for Systematic Reviews of Interventions [23] . Cochrane reviews frequently have been observed to have higher methodological quality, better reporting, and more precise conclusions than non-Cochrane reviews on the same topics [24] [25] [26] [27] [28] [29] . All Cochrane reviews undergo two peer reviews; once during the protocol stage and again after completion of the review before publication. Both protocols and completed reviews are published in the online Cochrane Library, where there are currently more than 2000 protocols and nearly 7000 completed reviews. Cochrane reviews are meant to be updated when new evidence becomes available, and many reviews in the Cochrane Library are currently on their fourth or later update. Cochrane reviews may therefore be expected to provide a high-quality, unbiased, and up-to-date assessment of the evidence on health care interventions such as probiotics.
Methods
To identify all reviews in the Cochrane Library whose primary focus was probiotics and the digestive system, two independent authors (EAP, TR) searched the titles and abstracts using the search term probiotic.* Each of the authors each read the title and abstract of every retrieved Cochrane review article to verify the inclusion of probiotics and disorders or symptoms affecting the digestive system. Cochrane reviews that included any trials comparing oral administration of probiotics to placebo or usual care were included in the present review. For this review, probiotics were defined as probiotics administered in any form (drink, powder, capsule) as a single species or as a cocktail of multiple species. Cochrane reviews that were withdrawn from publication or Cochrane reviews that contained trials where probiotic treatment was administered through enteral feedings were excluded. Cochrane reviews that did not feature comparisons that isolated the effects of probiotics also were excluded. For example, one Cochrane review compared oral bovine lactoferrin alone versus oral bovine lactoferrin in combination with a probiotic (L. rhamnosus GG) versus placebo [30] . Therefore, this Cochrane review did not include any comparisons isolating the effect of probiotics (e.g., probiotics alone versus placebo).
For each Cochrane review, the two authors extracted data on the number of trials included and the total number of participants. Because there is high variability in microbial composition in the GI system across the life span and changes in the microbiota are associated with increasing age [31] , we extracted data on the ages of participants included in the trials. We identified the prespecified outcomes of each Cochrane review as well as the Cochrane review authors' conclusions regarding the prespecified outcomes.
We assigned the conclusions from each Cochrane review into one of the following categories:
Category A: The Cochrane review indicated good evidence of a benefit from probiotics; Category B: The Cochrane review indicated good evidence of no benefit from probiotics; Category C: The Cochrane review indicated that there was not sufficient available evidence to allow benefits from probiotics to be determined. The Cochrane review conclusions were based on GRADE (Grading of Recommendations, Assessment, Development and Evaluation), which is Cochrane's preferred systematic approach for evaluating the quality of evidence for an estimate of effect, as high, moderate, low, or very low [32] . The criterion for good evidence (i.e., a rating of A or B) was at least one statement of "moderate" quality evidence of benefit or lack of benefit when GRADE was used. If the review had only "low" or "very low" quality evidence of benefit or lack of benefit, we assigned a rating of C. If GRADE was not used in the Cochrane review, the criterion was a precise effect estimate (e.g., statistical significance) for either benefit or lack of benefit and the authors only mentioned one serious deficiency in the evidence. For example, if there were statistically significant findings of benefit for the primary outcome, and the authors indicated that substantial heterogeneity between trials was the only serious deficiency in the evidence, the conclusions would be rated as A. If the review did not have a precise effect estimate for either benefit or lack of benefit, we assigned a C rating. This assignment was carried out by two reviewers making independent assessments of Cochrane review conclusions. In the case of disagreement between the two reviewers, a third reviewer adjudicated.
To determine factors that may influence clinical recommendations of probiotic use, we indicated the number of different probiotic combinations from each Cochrane review, as well as the number of trials that specified strain, dosage, intervention length, and follow-up. These variables provide important information regarding potential influences on probiotic efficacy in each trial and were collected from either the main text of the Cochrane review or the "Characteristics of included studies" tables for each trial. We also observed whether subgroup analyses on aspects of the intervention related to species and dosage of probiotics were proposed in the Cochrane review, and if there were sufficient data available to conduct these analyses. Finally, we noted whether adverse events were identified as a prespecified outcome and whether they were discussed within the review. Figure 1 shows the results of our search of the Cochrane Library. We identified 14 Cochrane reviews published between 2006 and 2015 that focused on probiotics and GI-related medical conditions, and grouped them into one of four categories: diarrhea, colitis, Crohn's disease, and liver conditions. Table 1 summarizes the number of trials, the number and age range of participants included in each Cochrane review, the outcomes assessed, and the conclusions in each of the Cochrane Reviews identified through search strategy ( N = 35 )
Results
Reviews not focused on GI conditions (n=13)
Reviews without probiotics intervention (n=2) Diarrhea reviews (n=5)
Reviews studying enteral administration of probiotics (n=4)
Reviews studying probiotics with an additional intervention (n=1)
Reviews withdrawn from CDSR (n=1) Fig. 1 . Results of searching Cochrane Database of Systematic Reviews (CDSR) for reviews on probiotics and gastrointestinal (GI) conditions. reviews. Overall, prespecified outcomes were generally similar among reviews within the same condition; however, there was substantial heterogeneity in how these outcomes were operationalized. Eight Cochrane reviews did not explicitly use GRADE to assess the quality of the evidence. Table 2 provides an overview of the intervention components described in each Cochrane review, including probiotics used and the number of trials that specified probiotic strain, dosage, intervention length, and duration of follow-up. Overall, L. rhamnosus GG (LGG) was the most commonly studied probiotic, appearing in 10 of the 14 Cochrane reviews, followed by VSL#3 (n ¼ 7) and Saccharomyces boulardii (n ¼ 6). When taking into account the number of RCTs included from the 160 trials, 100 (63%) specified the strain of the probiotic, 151 (94%) reported dosage, 126 (79%) specified intervention length, and 47 (29%) indicated duration of follow-up.
Full details of the probiotic species, strain, dosage, intervention length, and follow-up period studied in each trial in each of the Cochrane reviews can be found in Supplementary Table 1 . Although each of the 14 Cochrane reviews discussed adverse events (AEs) within the text of the review, only 116 of the 160 RCTs (73%) provided specific information regarding AEs. Three of the Cochrane reviews conducted meta-analyses on AEs; two did not find significant differences between the placebo and probiotic groups, and one reported a statistically significant decrease in the number of AEs reported in the probiotic group versus placebo. Among the 116 randomized individual trials, 2 reported AEs associated with LGG: mild GI upset with bloating and flatulence and nausea, epigastric pain, constipation, vomiting, and intolerance to medications. One RCT reported significantly more AEs among the S. boulardii group compared with placebo; symptoms included increase in thirst and constipation. Other reported AEs were generally mild. When examining the assessments of benefit from probiotics in each Cochrane review, four reviews were assigned an A rating, and the remaining 10 were assigned a C rating. There were no Cochrane reviews in which it was clear that probiotics were not beneficial (i.e., a B rating). A third reviewer was needed to adjudicate in one of the cases.
Diarrhea
We identified five reviews focused on treatment or prevention of diarrhea-related conditions, including pediatric antibioticassociated diarrhea, acute infectious diarrhea, and Clostridium difficile-associated diarrhea [33] [34] [35] [36] [37] . Two of the reviews focused on children, one focused on adults, and two studied both populations. Four of the five trials were assigned an A review conclusion status. Three of the reviews had sufficient data to assess all of their prespecified outcomes, and also performed subgroup analyses on factors related to species and dosage of probiotics. Of the two that did not perform subgroup analyses, one was limited by the small number of included trials and one did not mention whether subgroup analyses were intended. When taking into account the number of RCTs included from the Cochrane reviews focusing on diarrhea-related outcomes (125 trials), 65% specified probiotic strain and 98% indicated dosage. The proportion of trials that mentioned intervention length or follow-up was 73% and 36%, respectively. The incidence of AEs was addressed in all five Cochrane reviews, but was a prespecified outcome in only four; 26% of the included trials did not mention assessment of AEs. Regarding the degree of overlap of clinical trials between different Cochrane reviews, there was very little overlap in clinical trials included in each review. Three trials included in the 2013 review by Goldenberg et al. [36] were included in the 2015 review by AAD, antibiotic-associated diarrhea; AE, adverse event; CFU, colony-forming unit; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; GI, gastrointestinal; IPAA, ileal pouch-anal anastomosis; LOS, length of stay; QoL, quality of life; UC, ulcerative colitis * (A) the review indicated good evidence of benefit from probiotics; (B) the review indicated good evidence of no benefit from probiotics; (C) the review indicated that there was not sufficient available evidence to allow benefits from probiotics to be determined.
y Review conclusions are based on GRADE assessment for the primary outcomes and for adverse events if GRADE was used in the review. For reviews that did not explicitly use GRADE, a summary of the amount and type of evidence from the "Effects of interventions" section was provided.
z GRADE criteria used in the review. Goldenberg et al. [33] . There was one trial included in both Cochrane reviews by Bernaola et al. [34] and Allen et al. [35] .
Crohn's disease
We identified three Cochrane reviews assessing the efficacy of probiotics for Crohn's disease [38] [39] [40] . Two of the Cochrane reviews included patients of any age, and one did not specify the age of participants. All of the reviews received a C rating for the author conclusion statement. One review was able to assess one prespecified outcome; however, additional prespecified outcomes were not assessed due to lack of available data. Of the two remaining reviews, one assessed four of five prespecified outcomes, and the other was able to assess two prespecified outcomes. Two of the Cochrane reviews did not mention whether subgroup analyses were intended and one was unable to conduct subgroup analysis due to insufficient data. However, this review did not list or describe the proposed subgroup analyses in the methods. The three Cochrane reviews included 13 trials. Of these trials, 77% specified strain, 69% indicated dosage, 100% reported the length of the intervention, and 8% reported the duration of follow-up. AEs were a prespecified outcome in all three reviews; however, one review containing five trials did not specify which trials examined AEs and stated within the results text that the risk for withdrawal and serious AEs were similar to placebo. One trial overlapped in the Cochrane reviews by Rolfe et al. [38] and Doherty et al. [40] , and one trial overlapped in the Cochrane reviews by Rolfe et al. [38] and Butterworth et al. [39] .
Colitis
We found four Cochrane reviews evaluating the efficacy of probiotic therapy on the treatment of colitis [41] [42] [43] [44] . Two of the reviews did not specify age of participants included in the trials, one included adults >18 y of age, and one included patients of any age. All of the Cochrane reviews were classified as C author conclusion statement. Two of the reviews were able to assess all of the prespecified outcomes. One review was able to address two of six of their prespecified outcomes; the remaining 4 outcomes were unable to be assessed because of lack of available data. One Cochrane review was unable to complete meta-analyses due to differences in probiotics used, outcomes, and trial methodology. Subgroup analyses were not performed in any of the reviews. In one of the reviews, subgroup analyses were stated to have been planned but not performed due to insufficient data; however, this review did not list or describe the proposed subgroup analyses in the methods. None of the remaining Cochrane reviews mentioned whether subgroup analyses were intended. When considering the total number of RCTs included in these Cochrane reviews (N ¼ 15), 53% specified strains, 93% indicated dosage, 100% reported length of the intervention, and only 7% mentioned follow-up after treatment. The incidence of AEs was a prespecified outcome in all four Cochrane reviews; 80% of included trials mentioned assessment of AEs. None of the clinical trials was repeated among Cochrane reviews.
Liver conditions
Two Cochrane reviews focused on the effects of probiotics on liver conditions [45, 46] . One was an empty review [47] because the authors were unable to find any RCTs applicable to the topic of nonalcoholic steatohepatitis, or fatty liver disease. The second review included adults of various ages, depending on the trial criteria. This review was assigned a C rating for the author conclusions statement. This review assessed six of eight of the prespecified outcomes; the two remaining outcomes were not reported in the included trials and therefore could not be assessed. Statistically significant differences were noted in subgroup analyses by genus of probiotic and grade of hepatic encephalopathy. Seven RCTs were included in this review; of these, 14% specified strain, 71% specified dosage, and 100% reported intervention length. None of these trials reported follow-up. AEs were a prespecified outcome in both reviews and no significant differences in AEs were found between probiotic and placebo/no-intervention groups and in comparisons of AEs between probiotic and standard-therapy groups.
Discussion
Although probiotics are increasingly being used by both the general public and in clinical practice, inference based on the evidence is currently hampered due to heterogeneity in both the probiotics used in clinical trials and in the assessment of outcomes in these studies. To our knowledge, this was the first overview of Cochrane reviews of probiotics for GI-related medical conditions. The present review revealed that the heterogeneity in results appears to be related to the use of different probiotic types, doses, and treatment durations within clinical trials studying probiotics. There were a wide variety of probiotic species studied in the trials, [45] n/a n/a n/a n/a n/a McGee et al. (2011) [46] 7 1 (14) 5 (71) 7 (100) 0 (0) n/a, not applicable * Review paper lists the range of intervention length within the results text but it is not listed specifically for each study. of which many did not specify the dose and an even larger proportion did not define the strain. In many cases where strain and dosage was specified, trials using the same probiotic strain used different dosages. The present overview revealed that positive outcomes were generally observed with diarrhea-related conditions. All four Cochrane reviews that received an A conclusion indicating good evidence of benefit from probiotics focused on the diarrhea-related conditions. This likely reflects that these reviews, which were published between 2010 and 2015, include the most up-to-date and complete picture of currently available evidence. The present overview also revealed that there have been a number of clinical trials focused on probiotics in recent years. This is important because most of the C reviews were published before 2011 and might have had clearer conclusions (either A or B) if they included more recent evidence. The other three categories of GI disordersdCrohn's disease, colitis, and liver conditionsdcontained Cochrane reviews that received C conclusions, indicating that there was not sufficient available evidence to allow benefits from probiotics to be determined. Crohn's disease and colitis are two conditions associated with changes in the microbiota where primary treatment strategies focus on alleviating symptoms, inactivating the disease, and preventing relapses [48] . Growing evidence suggests a connection between alterations in the microbial composition of the gut and chronic liver diseases [49] . Probiotics are more commonly being used as a complementary approach to combat dysbiosis that is associated with these conditions [48, 49] . Searches for newer trials on probiotics for these conditions should be carried out so that the Cochrane reviews may be updated if appropriate, and the review evidence on probiotics may reflect the current underlying evidence base. Updating these older reviews and providing timely evidence should be a priority.
The complexity of the effects of probiotics on GI disorders is due in part to the fact that probiotics are formulated into many different products, including foods, dietary supplements, and functional foods. Furthermore, the term probiotics is often used as a catch all term for probiotics, prebiotics (nondigestible food ingredients that can stimulate the growth of gut bacteria), and synbiotics (a combination of a probiotic and prebiotic). The types of probiotics used including the strains, dosages, and length of intervention, have been highly variable, which complicates conclusions drawn from studying probiotics. It is extremely important to recognize that the health benefits attributed to probiotics significantly vary by strain [50] . As noted in Table 2 , there was a large variation in the number of trials that specified the strains used within the Cochrane reviews. It is critically important that clinical trials specify the strains of the species in the probiotic and do not solely provide the species, given the widely varying health-promoting effects by strain. Accordingly, systematic reviews and meta-analyses should report information on the strains of the probiotic species when these data are available.
Additionally, the majority of reviews and included trials did not address the issue of product storage or the quality of probiotics used within the trials. Most studies also did not confirm the viability or microbiologic identity of the probiotic species in the product, which likely has an influence on subsequent results. One review addressed the viability of the probiotics used within the trials, but this factor was not consistently addressed across reviews, possibly because it was not part of the individual trials.
To further complicate the interpretation of the results, >1000 different species and >3 million unique genes have been discovered within the microbiome [5,51,52]. Additionally, diversity of the microbiome significantly varies between healthy individuals; however, the pronounced difference is more commonly observed among infants and appears to diminish with age. More importantly, novel bacterial populations such as bifidobacteria and butyrate-producing colon bacteria [53] or Akkermansia muciniphila [54] are currently being studied for potential protective benefits given frequent associations with healthy microbiota in adults, which in the future could eventually be used as a treatment strategy to restore intestinal balance associated with inflammatory GI diseases. As the pool of research surrounding the microbiome expands, the interaction of these complex systems and probiotics within the human gut will continue to be explored.
In addition to the aforementioned concerns regarding the variability of the probiotics under study, there was substantial heterogeneity observed among the Cochrane reviews with respect to the outcomes assessed within trials. For example, Goldenberg et al. [33] reported that the primary investigators' definition of diarrhea varied among studies; among the 23 clinical trials included in this Cochrane review, nine different definitions of diarrhea were used. The use of standardized definitions for outcomes is important because if the outcomes are very different or defined in markedly different ways, they may not be appropriate for combining in a meta-analysis. Trials focused on the same health condition and intervention should ideally assess the same clinically meaningful outcomes and collect them in a similar fashion to allow pooling, meta-analysis, and comparison across trials. Core outcome sets can be useful because they ensure that trials collect the same outcomes in standard ways, which increases availability of the most important and relevant information for meta-analyses. One initiative focused on this work is COMET (Core Outcome Measures in Effectiveness Trials) [55] , which recommends including a minimum set of outcomes that should be measured and reported in clinical trials on a specific condition.
Subgroup analyses often are conducted in Cochrane reviews as a means of answering specific questions regarding certain patient or intervention characteristics that may explain some of the heterogeneity within the meta-analysis and reveal differences in intervention effects across subgroup factors. It is important for reviews to prespecify subgroup analyses to prevent study results from influencing which factors are investigated, and therefore possibly leading to misleading results [56] . In the present overview of Cochrane systematic reviews, approximately half of the reviews prespecified at least one subgroup analysis in the methods section; although in many instances, there were insufficient data to carry out the proposed subgroup analyses. Five of the 14 Cochrane reviews planned to examine the type of probiotic used, including dosage, species, or strain, and were unable to do so due to insufficient data. Clinical trials need to report this important information on the probiotics under study to apply these results to clinical practice, particularly given the wide range of probiotics and dosages used among the RCTs. Additionally, none of the reviews that mentioned subgroup analysis planned to examine differences in age. Given the age-related changes in the microbiome, this is an area that needs to be addressed in future studies.
There are a number of strengths of this Cochrane-focused overview of the effect of probiotics in GI disorders. Cochrane reviews are internationally recognized as the gold standard of evidence-based information in health care. The methodology used through Cochrane are further strengthened by a commitment to transparency and minimizing bias by undergoing rigorous peer-review process and avoiding conflicts of interest. The Cochrane collaboration also ensures quality by updating the reviews as new evidence emerges. Another strength of Cochrane reviews is that they specify AEs as a prespecified outcome. However, a large proportion of the individual RCTs included in the Cochrane reviews did not address AEs. Often, there was not a consistent record of AEs within the individual trials, so AE data could not be pooled for analysis. This is important when considering the safety of probiotics, and AEs should be included as a core outcome measure in future clinical trials of probiotics.
A limitation of the present study is that information on trials was extracted from the tables and the body of the text in the Cochrane reviews rather than directly from clinical trial reports. However, this may be expected to be an informative reflection of the evidence that was available to the authors of the Cochrane reviews. An additional limitation of this study is that the present overview did not include IBS as one of the GI conditions. IBS is one of the most common reasons that probiotics are consumed in clinical practice and also one of the most commonly studied, with >80 clinical trials of probiotics for IBS. Although there have been >50 systematic reviews, meta-analyses, or both focused on probiotics and GI conditions, to our knowledge, there has yet to be a completed Cochrane review evaluating probiotics for IBS. Cochrane is the gold standard of systematic reviews and future Cochrane reviews should focus on IBS, including both IBS with constipation and IBS with diarrhea, conditions for which probiotics often are used due to current lack of pharmacologic treatment options.
Conclusion
The results of the present overview of Cochrane systematic reviews of probiotics for GI disorders suggests that probiotics can have a beneficial effect on diarrheal conditions and related GI symptoms. Although encouraging, additional studies are needed to make conclusive inference on the efficacy of probiotics for colitis, Crohn's disease, and liver disorders. Among the reasons contributing to the inconclusive evidence for these disorders is the heterogeneity in the outcomes assessed across clinical trials, the variable quality of the reporting in the scientific literature on key details of the probiotics that were studied, and the even greater variability in the composition and quality of the probiotics used in the studies. Thus, future probiotics clinical trials, systematic reviews, and meta-analyses should specify important and often unreported details including the species, strain, dosage, and manufacturing processes and storage conditions of the probiotics used in the study. Additionally, future studies ideally should include core outcome measures that are collected in a standardized manner to allow for more precise assessment of probiotic efficacy. Future systematic reviews should evaluate these aspects of the probiotics intervention as well as whether patient characteristics (e.g., age, dietary intake, antibiotic usage, etc.) and treatment duration are related to treatment effect. Finally, there is a need for updated systematic reviews to reflect the totality of current trial evidence on probiotics interventions.
In the meantime, there are a variety of important issues when using probiotics to support GI health. For instance, the optimal timing for probiotic intervention in the human life span remains an area in need of additional clarity. Although some studies have suggested that the microbiota are relatively consistently colonized by early childhood, antibiotic-induced perturbations in the adult microbiota and the many supportive clinical trials and systematic reviews conducted among adult populations suggest that probiotics may offer benefits across the human life span. However, referring to the benefits of "probiotics" in a general sense is overly broad and much more specificity is required in this field to reflect the marked differences between various probiotics and more precisely inform the ways in which patients may benefit from probiotic intervention. In light of the varying strain-specific effects of many probiotic species, probiotics that specify the strain of each species in the product are preferable to help ensure known and desirable clinical effects. At present, only a select few commercially available probiotic supplements specify the strains of the probiotic microorganisms and more products should follow suit. Additionally, probiotic manufacturing, shipping, and storage processes can all affect the viability and maintenance of the desired dosage of the probiotic microorganisms by the time they are consumed. Probiotics used in research and clinical care ideally should be shipped and stored cold to ensure viability throughout the shipping and storage process. More generally, supportive evidence of the clinical effects and viable potency of the probiotics by the time they arrive to the clinic or consumer is of paramount importance for optimal efficacy. At present, there are no requirements for providing information on the strain, timing of administration, shipping and storage conditions, or evidence of potency on the labels of probiotic products. A consistent labeling standard for probiotics with information on these critical parameters would greatly help researchers, clinicians, and consumers make informed choices in the use of probiotics to support GI health. Although the focus of this overview has been on GI conditions, consideration of these issues would be important when using probiotics for other health purposes.
Supplemental Table 1 Full detailed description of intervention components included in Cochrane reviews of probiotics and GI conditions 
